« Return to News | Drug Sponsors

Abbott selects “AbbVie” as new name for future pharma company

Thursday, March 22, 2012 06:30 AM

Abbott has dubbed its new, independent research-based pharmaceutical company AbbVie (pronounced Abb-vee), which it will launch by the end of 2012.

Abbott chose the name as a combination of Abbott and “vie,” which is a reference to the Latin root “vi” meaning “life.”

"The beginning of the name connects the new company to Abbott and its heritage of pioneering science. The 'vie' calls attention to the vital work the company will continue to advance to improve the lives of people around the world," said Richard A. Gonzalez, executive vice president of global pharmaceuticals at Abbott. Gonzalez will be heading AbbVie as chairman and CEO.

The naming of the new company is the latest milestone in the process that began in October 2011, when Abbott announced it would separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. AbbVie, the research-based pharmaceutical company, will include Abbott’s current portfolio of leading proprietary pharmaceuticals and biologics. The diversified medical products company, which will retain the Abbott name, will consist of Abbott’s existing diversified medical products portfolio, including its branded generic pharmaceutical, devices, diagnostics and nutritional businesses.

The AbbVie logo and graphic identity will be unveiled when the new company is launched.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.